Antibody-Drug Conjugates
WuXi XDC Plans $470.5M IPO to Drive Global Manufacturing Expansion
WuXi’s spinoff venture, WuXi XDC, is poised to make its debut on the Hong Kong Stock Exchange later this month, ...
Merck Drops Two Cancer ADCs from Kelun Deal, Focuses on Daiichi Sankyo
Merck & Co. is refining its strategy in the realm of antibody-drug conjugates (ADCs). Shortly after a $4 billion acquisition ...
Merck and Daiichi join forces to develop novel cancer drugs in $22B deal
In a strategic move, Merck & Co. has solidified its position in the thriving field of antibody-drug conjugates (ADCs) through ...
Lilly acquires European biotech Elahere, expands its ADC network and pipeline
Eli Lilly is actively expanding its involvement in the burgeoning field of antibody-drug conjugates (ADCs) in Europe. Following its recent ...
Lonza to boost ADC production capacity and hire 180 new staff
Despite the unexpected departure of Lonza’s CEO last month, the Swiss Contract Development and Manufacturing Organization (CDMO) remains a force ...
AstraZeneca and Daiichi Reach Key Milestone in Breast Cancer ADC Trial, Paving Way to Challenge Gilead
AstraZeneca and Daiichi Sankyo are making a strategic move to challenge Gilead Sciences’ position in the breast cancer arena. They ...
Seagen’s Tukysa Demonstrates Trial Victory in Breast Cancer, Amplifying Roche’s Kadcyla and Significance in Light of Pfizer’s $43B Acquisition
In a strategic move, Pfizer has announced a hefty investment of $43 billion to acquire Seagen, with a keen focus ...
Daiichi Sankyo to Dominate Antibody-Drug Conjugates Market by 2029
Daiichi has successfully established ADCs (Antibody-Drug Conjugates) as a significant therapeutic approach, overcoming previous years of underwhelming results. Even though ...
How BCMA-targeted therapies are changing the game for multiple myeloma
Imagine a world where you could treat cancer with a simple injection or infusion, without the need for surgery, chemotherapy, ...
Lonza Bolsters Antibody-Drug Conjugates Portfolio with Synaffix Acquisition
Lonza, a global manufacturing company acquired Synaffix B.V., a biotechnology company specializing in the advancement of ADCs (antibody-drug conjugates) through ...
